Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis

Authors

Iyad Alnahhas, Thomas Jefferson UniversityFollow
Mouaz Alsawas, Mayo Clinic
Appaji Rayi, The Ohio State University Wexner Medical Center
Joshua D Palmer, The Ohio State University Wexner Medical Center
Raju Raval, The Ohio State University Wexner Medical Center
Shirley Ong, The Ohio State University Wexner Medical Center
Pierre Giglio, The Ohio State University Wexner Medical Center
Mohammad Hassan Murad, Mayo Clinic
Vinay Puduvalli, The Ohio State University Wexner Medical Center

Document Type

Article

Publication Date

7-10-2021

Comments

This article is the author’s final published version in Neuro-Oncology Advances, Volume 3, Issue 1, July 2021, Article number vdab095.

The published version is available at https://doi.org/10.1093/noajnl/vdab095. Copyright © Alnahhas et al.

Abstract

[This corrects the article DOI: 10.1093/noajnl/vdaa082.].

Recommended Citation

Alnahhas, Iyad; Alsawas, Mouaz; Rayi, Appaji; Palmer, Joshua D; Raval, Raju; Ong, Shirley; Giglio, Pierre; Murad, Mohammad Hassan; and Puduvalli, Vinay, "Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis" (2021). Department of Neurology Faculty Papers. Paper 287.
https://jdc.jefferson.edu/neurologyfp/287

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

PubMed ID

34258581

Language

English